Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas
Pharma
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Three Chinese obesity assets are featured in Verdiva's $410 million debut. Experts analyzed the buyout prospects of Legend and BeiGene. Plus more.
Angus Liu
Jan 10, 2025 9:00am
Merck's GLP-1 play; Astellas' AAV deal—Fierce Pharma Asia
Dec 20, 2024 8:51am
Study says top launches were for drugs for untreated diseases
Nov 6, 2024 9:55am
AstraZeneca, GSK, Takeda—Fierce Pharma Asia
Nov 1, 2024 8:20am
Astellas pulls application for Izervay after talks with CHMP
Oct 28, 2024 11:07am
Astellas, Otsuka, Samsung Biologics—Fierce Pharma Asia
Oct 25, 2024 8:43am
